Real-world data on Nuvaxovid adverse events are in
The first information on Australian patients’ experiences of the new COVID-19 shot shows how its safety profile differs from other vaccines
The first safety data for Novavax’s COVID-19 vaccine have been analysed and show more cases of fatigue and headache than after Comirnaty but fewer injection-site reactions.
More than 35,000 doses of the protein subunit vaccine, Nuvaxovid, have gone into arms since it received TGA and ATAGI approval in January.